Old Web
English
Sign In
Acemap
>
authorDetail
>
Thomas Genna
Thomas Genna
IMP dehydrogenase
Pharmacology
Medicine
Pharmacokinetics
Cmax
4
Papers
12
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A Phase I Dose‐Ranging Study of the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of AVN944, an IMPDH Inhibitor, in Healthy Male Volunteers
2009
The Journal of Clinical Pharmacology
J. Michael Hamilton
Matthew W. Harding
Thomas Genna
David K. Bol
Show All
Source
Cite
Save
Citations (9)
Characterization of a myeloid leukemia cell line resistant to inosine monophosphate dehydrogenase (IMPDH) inhibition: correlation of molecular pathway markers and GTP depletion with clinical biomarkers.
2008
Cancer Research
Jeffrey Strovel
Tammy Lawrence
Martin Korade
Pachai Natarajan
Karina Zuck
Stephen Glanowski
Thomas Genna
Simon Katz
Stephen K. Horrigan
J. Michael Hamilton
David K. Bol
Show All
Source
Cite
Save
Citations (0)
A phase I trial of AVN944 in patients with advanced hematologic malignancies
2007
Journal of Clinical Oncology
Rebecca B. Klisovic
Guido Tricot
Steven Coutre
Tibor Kovacsovics
F. Giles
Thomas Genna
David K. Bol
Jeffrey Strovel
J. M. Hamilton
Beverly S. Mitchell
Show All
Source
Cite
Save
Citations (2)
Clinical-Biomarker Correlations in Adult AML Patients in a Phase I Trial of AVN944 Support Observations of Clinical Effect and Provide Hypotheses for Patient Selection Criteria for Further Clinical Trials.
2007
Blood
Rebecca B. Klisovic
Steven Coutre
Tibor Kovacsovics
Hagop M. Kantarjiam
Guido Tricot
Jeffrey Strovel
Thomas Genna
David K. Bol
Michael Hamilton
Beverly S. Mitchell
Show All
Source
Cite
Save
Citations (1)
1